home genetic news bioinformatics biotechnology literature journals ethics positions events sitemap

UBBFriend: Email This Page to Someone!
  Biotechnical requests and sources
  AnaSpec Introduces Beta- Secretase Enzyme & Assay

Post New Topic  Post A Reply
profile | register | preferences | faq | search

next newest topic | next oldest topic
Author Topic:   AnaSpec Introduces Beta- Secretase Enzyme & Assay
posted 10-16-2009 06:39 PM     Click Here to See the Profile for anaspec   Click Here to Email anaspec     Edit/Delete Message Reply w/Quote
Fremont, CA – October 16, 2009

As one of the world’s largest providers of beta-amyloid peptides and Alzheimer’s related research products, AnaSpec has announced its latest offering – the human recombinant beta-secretase enzyme.

b- secretase (BACE1) is a key protease involved in the production of beta-amyloid peptides found in extracellular amyloid plaques of patients with Alzheimer’s disease (AD).1 This enzyme has been implicated as an important target for anti-amyloid therapy of AD.2

The recombinant human BACE1 contains the catalytic domain and a C-terminal His tag. The protein was expressed as inclusion bodies in E. coli. It was refolded and purified using ion exchange and IMAC chromatography.3 Enzyme activity can been measured in fluorescence resonance energy transfer (FRET) substrate based assays (e.g. SensoLyte® 520 beta-Secretase Assay Kit, cat# 71144). 100 ng of b-secretase is sufficient for this FRET-based assay.

AnaSpec’s SensoLyte™ 520 b-Secretase Assay Kit (cat# 71144) is the industry’s only long wavelength assay kit in the green range. This kit is a fluorimetric assay kit and is sensitive, robust and easy-to-use. It employs a FRET peptide (mentioned above), facilitating high throughput screening of beta-secretase targeting drug candidates. The sequence of this FRET peptide is derived from the beta-secretase cleavage site of beta-amyloid precursor protein (APP) with Swedish mutation. This mutation enhances the susceptibility of APP to beta-secretase and results in an early onset of AD.

1. Willem, M. et al. Semin Cell Dev Biol. 20,175 (2009).
2. Ghosh, K. et al. Neurotherapeutics 5, 399 (2008).
3. Tomasselli, G. et al. Protein & Peptide Letters. 15,131 (2008).

About AnaSpec

AnaSpec is a leading provider of integrated proteomics solutions to the world’s largest biotech, pharmaceutical, and academic research institutions. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and antibodies.

For more information visit www.anaspec.com



All times are ET (US)

next newest topic | next oldest topic

Administrative Options: Close Topic | Archive/Move | Delete Topic
Post New Topic  Post A Reply
Hop to:

Contact Us | HUM-MOLGEN

Copyright by HUM-MOLGEN 1995-2017

Powered by: Ultimate Bulletin Board, Version 5.44a
© Infopop Corporation (formerly Madrona Park, Inc.), 1998 - 2000.